The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis

BMC Endocrine Disorders

Victor M Montori⁴  Tarig Elraiyah⁵  Lars Berglund¹  Patricia J Erwin⁵  Melanie A Lane⁵  Irina Bancos⁴  Shabnum Gupta⁵  Svitlana Dzyubak⁵  Fernando Coto-Yglesias⁵  Ahmad Hazem²  M Hassan Murad³ 

[1] Davis and the VA Northern California Health Care System, University of California, Sacramento, USA;Department of Internal Medicine, University of North Dakota, Fargo, ND, USA;Division of Preventive Medicine, Mayo Clinic, Rochester, MN, USA;Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, MN, USA;Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA

关键词: Systematic reviews and meta-analysis;    Pancreatitis;    Cardiovascular disease;    Hypertriglyceridemia;   

Others  :  1086463
DOI  :  10.1186/1472-6823-12-2

 received in 2012-01-06, accepted in 2012-03-31,  发布年份 2012

【 摘 要 】

Background

Hypertriglyceridemia may be associated with important complications. The aim of this study is to estimate the magnitude of association and quality of supporting evidence linking hypertriglyceridemia to cardiovascular events and pancreatitis.

Methods

We conducted a systematic review of multiple electronic bibliographic databases and subsequent meta-analysis using a random effects model. Studies eligible for this review followed patients longitudinally and evaluated quantitatively the association of fasting hypertriglyceridemia with the outcomes of interest. Reviewers working independently and in duplicate reviewed studies and extracted data.

Results

35 studies provided data sufficient for meta-analysis. The quality of these observational studies was moderate to low with fair level of multivariable adjustments and adequate exposure and outcome ascertainment. Fasting hypertriglyceridemia was significantly associated with cardiovascular death (odds ratios (OR) 1.80; 95% confidence interval (CI) 1.31-2.49), cardiovascular events (OR, 1.37; 95% CI, 1.23-1.53), myocardial infarction (OR, 1.31; 95% CI, 1.15-1.49), and pancreatitis (OR, 3.96; 95% CI, 1.27-12.34, in one study only). The association with all-cause mortality was not statistically significant.

Conclusions

The current evidence suggests that fasting hypertriglyceridemia is associated with increased risk of cardiovascular death, MI, cardiovascular events, and possibly acute pancreatitis.

Précis: hypertriglyceridemia is associated with increased risk of cardiovascular death, MI, cardiovascular events, and possibly acute pancreatitis

【 授权许可】

   
2012 Murad et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH: Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009, 169(6):572-578.
• [2]Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115(4):450-458.
• [3]Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3(2):213-219.
• [4]Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004, 110(17):2678-2686.
• [5]Toskes PP: Hyperlipidemic pancreatitis. Gastroenterol Clin North Am 1990, 19(4):783-791.
• [6]Brunzell JD, Schrott HG: The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. Trans Assoc Am Physicians 1973, 86:245-254.
• [7]Scriver C, Beaudet A, Sly W, Valle D, Brunzell J, Deeb SI (Eds): Familial lipoprotein lipase deficiency, ApoC-II deficiency, and hepatic lipase deficiency In The Metabolic Basis of Inherited Disease. 8th edition. New York: McGraw-Hill; 2001:2789-2816.
• [8]Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e1000097.
• [9]Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute
• [10]Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM: A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 2008, 93(3):666-673.
• [11]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
• [12]Egger M, Davey Smith G, Schneider M, Minder Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
• [13]Acarturk E, Cayli M, Akpinar O, Attila G, Demir M: Relation between age and gender differences in plasma triglyceride concentrations and coronary artery disease in Southern Turkey. Clin Chim Acta 2004, 339(1-2):123-128.
• [14]Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298(3):309-316.
• [15]Barrett-Connor E, Khaw KT: Borderline fasting hypertriglyceridemia: absence of excess risk of all-cause and cardiovascular disease mortality in healthy men without hypercholesterolemia. Prev Med 1987, 16(1):1-8.
• [16]Bass KM, Newschaffer CJ, Klag MJ, Bush TL: Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993, 153(19):2209-2216.
• [17]Bonaventure A, Kurth T, Pico F, Barberger-Gateau P, Ritchie K, Stapf C, Tzourio C: Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: the three-city study. Atherosclerosis 2010, 210(1):243-248.
• [18]Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223(5):405-418.
• [19]Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, Osaki R, Cockram CS, Chan JC: Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev 2005, 21(2):183-188.
• [20]Chester M, Chen L, Kaski JC: Identification of patients at high risk for adverse coronary events while awaiting routine coronary angioplasty. Br Heart J 1995, 73(3):216-222.
• [21]Czernichow S, Bruckert E, Bertrais S, Galan P, Hercberg S, Oppert JM: Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men. Int J Obes (Lond) 2007, 31(5):791-796.
• [22]Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH: Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005, 28(1):101-107.
• [23]Eberly LE, Stamler J, Neaton JD: Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003, 163(9):1077-1083.
• [24]Egger M, Smith GD, Pfluger D, Altpeter E, Elwood PC: Triglyceride as a risk factor for ischaemic heart disease in British men: effect of adjusting for measurement error. Atherosclerosis 1999, 143(2):275-284.
• [25]Ellingsen I, Hjermann I, Abdelnoor M, Hjerkinn EM, Tonstad S: Dietary and antismoking advice and ischemic heart disease mortality in men with normal or high fasting triacylglycerol concentrations: a 23-y follow-up study. Am J Clin Nutr 2003, 78(5):935-940.
• [26]Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997, 96(8):2520-2525.
• [27]Goldberg RJ, Urowitz MB, Ibanez D, Nikpour M, Gladman DD: Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009, 36(11):2454-2461.
• [28]Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS: The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2006, 21(10):2881-2892.
• [29]Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, Goldbourt U: Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) registry. Circulation 1999, 100(5):475-482.
• [30]Hoogeveen RC, Gambhir JK, Gambhir DS, Kimball KT, Ghazzaly K, Gaubatz JW, Vaduganathan M, Rao RS, Koschinsky M, Morrisett JD: Evaluation of Lp[a] and other independent risk factors for CHD in Asian Indians and their USA counterparts. J Lipid Res 2001, 42(4):631-638.
• [31]Jonsdottir LS, Sigfusson N, Guonason V, Sigvaldason H, Thorgeirsson G: Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik study. J Cardiovasc Risk 2002, 9(2):67-76.
• [32]Lamarche B, Despres JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ: Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular study). Am J Cardiol 1995, 75(17):1189-1195.
• [33]Lloret Linares C, Pelletier AL, Czernichow S, Vergnaud AC, Bonnefont-Rousselot D, Levy P, Ruszniewski P, Bruckert E: Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008, 37(1):12-13.
• [34]Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WMJ, Robbins DC, Howard BV: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The strong heart study. Diabetes Care 2003, 26(1):16-23.
• [35]Malone DC, Boudreau DM, Nichols GA, Raebel MA, Fishman PA, Feldstein AC, Ben-Joseph RH, Okamoto LJ, Boscoe AN, Magid DJ: Association of cardiometabolic risk factors and prevalent cardiovascular events. Metab Syndr Relat Disord 2009, 7(6):585-593.
• [36]Mazza A, Tikhonoff V, Schiavon L, Casiglia E: Triglycerides + high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the CArdiovascular STudy in the ELderly. Intern Med J 2005, 35(10):604-610.
• [37]Mora S, Rifai N, Buring JE, Ridker PM: Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008, 118(10):993-1001.
• [38]Noda H, Maruyama K, Iso H, Dohi S, Terai T, Fujioka S, Goto K, Horie S, Nakano S, Hirobe K: Prediction of myocardial infarction using coronary risk scores among Japanese male workers: 3M study. J Atheroscler Thromb 2010, 17(5):452-459.
• [39]Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341(6):410-418.
• [40]Samuelsson O, Hedner T, Persson B, Andersson O, Berglund G, Wilhelmesen L: The role of diabetes mellitus and hypertriglyceridaemia as coronary risk factors in treated hypertension: 15 years of follow-up of antihypertensive treatment in middle-aged men in the Primary Prevention Trial in Goteborg, Sweden. J Intern Med 1994, 235(3):217-227.
• [41]Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R: Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 2005, 53(2):219-226.
• [42]Sprecher DL, Pearce GL, Park EM, Pashkow FJ, Hoogwerf BJ: Preoperative triglycerides predict post-coronary artery bypass graft survival in diabetic patients: a sex analysis. Diabetes Care 2000, 23(11):1648-1653.
• [43]Tanko LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C: Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 2005, 111(15):1883-1890.
• [44]Tsai SP, Wen CP, Chan HT, Chiang PH, Tsai MK, Cheng TY: The effects of pre-disease risk factors within metabolic syndrome on all-cause and cardiovascular disease mortality. Diabetes Res Clin Pract 2008, 82(1):148-156.
• [45]Upmeier E, Lavonius S, Lehtonen A, Viitanen M, Isoaho H, Arve S: Serum lipids and their association with mortality in the elderly: A prospective cohort study. Aging Clin Exp Res 2009, 21(6):424-430.
• [46]Valdivielso P, Sanchez-Chaparro MA, Calvo-Bonacho E, Cabrera-Sierra M, Sainz-Gutierrez JC, Fernandez-Labandera C, Fernandez-Meseguer A, Quevedo-Aguado L, Moraga MR, Galvez-Moraleda A, et al.: Association of moderate and severe hypertriglyceridemia with obesity, diabetes mellitus and vascular disease in the Spanish working population: results of the ICARIA study. Atherosclerosis 2009, 207(2):573-578.
• [47]Weir CJ, Sattar N, Walters MR, Lees KR: Low triglyceride, not low cholesterol concentration, independently predicts poor outcome following acute stroke. Cerebrovasc Dis 2003, 16(1):76-82.
• [48]Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH: Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007, 297(5):468-470.
• [49]Labreuche J, Deplanque D, Touboul PJ, Bruckert E, Amarenco P: Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis. Atherosclerosis 2010, 212(1):9-15.
• [50]Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, Swiglo BA, Isley WL, Guyatt GH, Montori VM: Patient-important outcomes in registered diabetes trials. JAMA 2008, 299(21):2543-2549.
• [51]Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P: Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2011, 57(2):267-272.
• [52]Loomba RS, Arora R: Prevention of cardiovascular disease utilizing fibrates-a pooled meta-analysis. Am J Ther 2010, 17(6):e182-e188.
• [53]Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375(9729):1875-1884.
• [54]Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B: Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis. Atherosclerosis 2011.
• [55]Bruckert E, Labreuche J, Amarenco P: Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210(2):353-361.
• [56]Duggal JK, Singh M, Attri N, Singh PP, Ahmed N, Pahwa S, Molnar J, Singh S, Khosla S, Arora R: Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther 2010, 15(2):158-166.
• [57]Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, et al.: Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363(3):233-244.
• [58]AIM-HIGH Investigators: The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011, 161(3):471-477. e472